A little belated news. Gilead Science (GILD), reported on April 22, that their first quarter profit rose 21 percent due mainly to increase sales of its drugs for treating AIDS. Source: http://finance.yahoo.com/news/Gilead-profit-rises-a-rb-14997225.html?.v=1 Today, we can also see GILD at play due to the Mexican Swine flu. On the Ichimoku chart, it has just break out [...]
-
Recent Posts
-
Categories
- Agriculture
- Automotive
- Bond
- Book Review
- Commodities
- Consumer Cyclical (Footwear)
- Consumer Goods
- DOW
- Energy
- ETF
- Financials
- Forex
- Healthcare
- HKSE
- HSI
- Infrastructure
- Leisure
- NASDAQ
- Options Trading
- Property
- Publishing
- REIT
- Retail
- Russell 2000
- S&P500
- Services
- Solar
- SSE
- STI
- TA
- Tech
- Thinkorswim
- Transport
- Travel
- Uncategorized
- VIX
